Merck & Co. Inc.is studying GE Healthcare’s investigational positron emission tomography imaging agent flutemetamol as a potential companion diagnostic for its Alzheimer’s disease therapy, MK-8931, under a partnership announced Dec. 18.
The announcement comes on the heels of Merck’s Dec. 3 announcement that it started a phase II/III study of the...